vs
Side-by-side financial comparison of Biogen (BIIB) and Xerox Holdings Corp (XRX). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.3B vs $2.0B, roughly 1.1× Xerox Holdings Corp). On growth, Xerox Holdings Corp posted the faster year-over-year revenue change (25.7% vs -7.1%). Biogen produced more free cash flow last quarter ($468.0M vs $192.0M). Over the past eight quarters, Xerox Holdings Corp's revenue compounded faster (16.2% CAGR vs -0.2%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Xerox Corporation is an American corporation that sells printers, digital document products and services in more than 160 countries. Xerox was the pioneer of the photocopier market, beginning with the introduction of the Xerox 914 in 1959, so much so that the word xerox is commonly used as a synonym for photocopy. Xerox is headquartered in Norwalk, Connecticut, though it is incorporated in New York with its largest group of employees based around Rochester, New York, where the company was fou...
BIIB vs XRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $2.0B |
| Net Profit | $-48.9M | — |
| Gross Margin | 78.3% | — |
| Operating Margin | -2.5% | — |
| Net Margin | -2.1% | — |
| Revenue YoY | -7.1% | 25.7% |
| Net Profit YoY | -118.3% | — |
| EPS (diluted) | $-0.35 | $-0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $2.0B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $1.6B | ||
| Q1 25 | $2.4B | $1.5B | ||
| Q4 24 | $2.5B | $1.6B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B | ||
| Q1 24 | $2.3B | $1.5B |
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | $-760.0M | ||
| Q2 25 | $634.8M | $-106.0M | ||
| Q1 25 | $240.5M | $-90.0M | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | $-1.2B | ||
| Q2 24 | $583.6M | $18.0M | ||
| Q1 24 | $393.4M | $-113.0M |
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.3% | — |
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | -38.8% | ||
| Q2 25 | 24.0% | -6.7% | ||
| Q1 25 | 9.9% | -6.2% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | -78.9% | ||
| Q2 24 | 23.7% | 1.1% | ||
| Q1 24 | 17.2% | -7.5% |
| Q4 25 | $-0.35 | $-0.62 | ||
| Q3 25 | $3.17 | $-6.01 | ||
| Q2 25 | $4.33 | $-0.87 | ||
| Q1 25 | $1.64 | $-0.75 | ||
| Q4 24 | $1.82 | $-0.21 | ||
| Q3 24 | $2.66 | $-9.71 | ||
| Q2 24 | $4.00 | $0.11 | ||
| Q1 24 | $2.70 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $512.0M |
| Total DebtLower is stronger | $6.3B | $4.0B |
| Stockholders' EquityBook value | $18.3B | $444.0M |
| Total Assets | $29.4B | $9.8B |
| Debt / EquityLower = less leverage | 0.34× | 9.05× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $512.0M | ||
| Q3 25 | — | $479.0M | ||
| Q2 25 | — | $449.0M | ||
| Q1 25 | — | $336.0M | ||
| Q4 24 | — | $576.0M | ||
| Q3 24 | — | $521.0M | ||
| Q2 24 | — | $485.0M | ||
| Q1 24 | — | $685.0M |
| Q4 25 | $6.3B | $4.0B | ||
| Q3 25 | $6.3B | $4.1B | ||
| Q2 25 | $6.3B | $3.5B | ||
| Q1 25 | $4.5B | $2.7B | ||
| Q4 24 | $6.3B | $2.8B | ||
| Q3 24 | $4.5B | $2.8B | ||
| Q2 24 | $6.3B | $3.2B | ||
| Q1 24 | $6.3B | $3.2B |
| Q4 25 | $18.3B | $444.0M | ||
| Q3 25 | $18.2B | $365.0M | ||
| Q2 25 | $17.6B | $1.1B | ||
| Q1 25 | $17.0B | $1.1B | ||
| Q4 24 | $16.7B | $1.1B | ||
| Q3 24 | $16.4B | $1.3B | ||
| Q2 24 | $15.9B | $2.4B | ||
| Q1 24 | $15.2B | $2.4B |
| Q4 25 | $29.4B | $9.8B | ||
| Q3 25 | $29.2B | $10.1B | ||
| Q2 25 | $28.3B | $8.9B | ||
| Q1 25 | $28.0B | $8.2B | ||
| Q4 24 | $28.0B | $8.4B | ||
| Q3 24 | $28.3B | $8.3B | ||
| Q2 24 | $26.8B | $9.5B | ||
| Q1 24 | $26.6B | $9.9B |
| Q4 25 | 0.34× | 9.05× | ||
| Q3 25 | 0.35× | 11.10× | ||
| Q2 25 | 0.36× | 3.11× | ||
| Q1 25 | 0.27× | 2.56× | ||
| Q4 24 | 0.38× | 2.62× | ||
| Q3 24 | 0.28× | 2.11× | ||
| Q2 24 | 0.40× | 1.34× | ||
| Q1 24 | 0.41× | 1.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $208.0M |
| Free Cash FlowOCF − Capex | $468.0M | $192.0M |
| FCF MarginFCF / Revenue | 20.5% | 9.5% |
| Capex IntensityCapex / Revenue | 1.9% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | $187.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $208.0M | ||
| Q3 25 | $1.3B | $116.0M | ||
| Q2 25 | $160.9M | $-11.0M | ||
| Q1 25 | $259.3M | $-89.0M | ||
| Q4 24 | $760.9M | $351.0M | ||
| Q3 24 | $935.6M | $116.0M | ||
| Q2 24 | $625.8M | $123.0M | ||
| Q1 24 | $553.2M | $-79.0M |
| Q4 25 | $468.0M | $192.0M | ||
| Q3 25 | $1.2B | $104.0M | ||
| Q2 25 | $134.3M | $-15.0M | ||
| Q1 25 | $222.2M | $-94.0M | ||
| Q4 24 | $721.6M | $346.0M | ||
| Q3 24 | $900.6M | $108.0M | ||
| Q2 24 | $592.3M | $117.0M | ||
| Q1 24 | $507.3M | $-87.0M |
| Q4 25 | 20.5% | 9.5% | ||
| Q3 25 | 48.4% | 5.3% | ||
| Q2 25 | 5.1% | -1.0% | ||
| Q1 25 | 9.1% | -6.5% | ||
| Q4 24 | 29.4% | 21.5% | ||
| Q3 24 | 36.5% | 7.1% | ||
| Q2 24 | 24.0% | 7.4% | ||
| Q1 24 | 22.1% | -5.8% |
| Q4 25 | 1.9% | 0.8% | ||
| Q3 25 | 1.8% | 0.6% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 1.5% | 0.3% | ||
| Q4 24 | 1.6% | 0.3% | ||
| Q3 24 | 1.4% | 0.5% | ||
| Q2 24 | 1.4% | 0.4% | ||
| Q1 24 | 2.0% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | 6.83× | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
XRX
| Other | $596.0M | 29% |
| Manufactured Product Other | $485.0M | 24% |
| Supplies Paper And Other Sales | $483.0M | 24% |
| IT Solutions Segment | $155.0M | 8% |
| CA | $128.0M | 6% |
| IT Products | $100.0M | 5% |
| Rental And Other | $52.0M | 3% |
| Financial Service | $29.0M | 1% |
